OFFRE D'UNE DURÉE LIMITÉE | Obtenez 3 mois à 0.99 $ par mois

14.95 $/mois par la suite. Des conditions s'appliquent.
Page de couverture de MyFSHD

MyFSHD

MyFSHD

Auteur(s): Peter L Jones PhD
Écouter gratuitement

À propos de cet audio

 MyFSHD is about education and personal empowerment for the worldwide facioscapulohumeral muscular dystrophy (FSHD) community. Here we have discussions and commentary hosted by FSHD researcher Peter Jones, PhD, on many things of interest to the FSHD community. Learn about the science behind the different FSHD therapeutic approaches, FSHD pathology, family genetics and FSHD diagnostics. We will discuss upcoming clinical trials and what to look forward to. You will get to understand how you can be better prepared, become involved, and help contribute to defeating FSHD once and for all.Peter L Jones, PhD Développement commercial et entrepreneuriat Entrepreneurship Gestion et leadership Économie
Épisodes
  • Our takes on recent (~Jan 2026) clinical trial updates

    Our takes on recent (~Jan 2026) clinical trial updates
    Jan 15 2026

    "So, Mr Tipton, how could it take you five minutes to cook your grits when it takes the entire grit-eating world twenty minutes?" We discuss the initial Epicrispr Biotech press release pertaining to their EPI-321 phase 1/2 clinical trial and the big picture science behind the RESTEM phase 1/2 clinical trial in progress and the Scholar Rock upcoming phase 2 clinical trial.
    Voir plus Voir moins
    46 min
  • All-in-one version of our evaluation of EPI-321 data and trial

    All-in-one version of our evaluation of EPI-321 data and trial
    Sep 14 2025

    "There's another old saying, Senator: Don't piss down my back and tell me it's raining." We know a lot of you don't have the time or interest in all the details so we packaged up the highlights of the gene therapy series, with some new information and evaluation, too, into one shorter (but not short enough, we know) episode.
    Voir plus Voir moins
    1 h et 36 min
  • Our evaluation and opinions of the EPI-321 clinical trial design and potential based on the pre-clinical data

    Our evaluation and opinions of the EPI-321 clinical trial design and potential based on the pre-clinical data
    Sep 6 2025

    "But did you bleed him? - Aesculapius says that bleeding is not a cure. It is only a way of proving that you are a physician at the expense of your patient." Finally, we discuss the EPI-321 epigenetic editing phase I/II clinical trial design and its potential for answering key questions necessary for going to phase III and for providing benefit to participants and patients.
    Voir plus Voir moins
    46 min
Pas encore de commentaire